X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PLETHICO PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PLETHICO PHARMA ASTRAZENECA PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 120.7 -1.1 - View Chart
P/BV x 17.2 0.0 102,577.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
PLETHICO PHARMA
Mar-14
ASTRAZENECA PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,285395 325.4%   
Low Rs63431 2,025.6%   
Sales per share (Unadj.) Rs189.6604.4 31.4%  
Earnings per share (Unadj.) Rs-0.232.5 -0.6%  
Cash flow per share (Unadj.) Rs3.851.3 7.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6473.6 14.5%  
Shares outstanding (eoy) m25.0034.08 73.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.10.4 1,435.4%   
Avg P/E ratio x-4,712.76.6 -71,826.5%  
P/CF ratio (eoy) x249.64.2 6,011.3%  
Price / Book Value ratio x14.00.5 3,106.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9887,262 330.3%   
No. of employees `0001.6NA-   
Total wages/salary Rs m1,6051,596 100.5%   
Avg. sales/employee Rs Th3,040.2NM-  
Avg. wages/employee Rs Th1,029.2NM-  
Avg. net profit/employee Rs Th-3.3NM-  
INCOME DATA
Net Sales Rs m4,74020,598 23.0%  
Other income Rs m92386 23.8%   
Total revenues Rs m4,83220,984 23.0%   
Gross profit Rs m-1302,818 -4.6%  
Depreciation Rs m101642 15.8%   
Interest Rs m01,593 0.0%   
Profit before tax Rs m-139969 -14.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5-138 -3.7%   
Profit after tax Rs m-51,107 -0.5%  
Gross profit margin %-2.713.7 -20.0%  
Effective tax rate %-3.7-14.3 25.6%   
Net profit margin %-0.15.4 -2.0%  
BALANCE SHEET DATA
Current assets Rs m2,72618,877 14.4%   
Current liabilities Rs m2,43511,896 20.5%   
Net working cap to sales %6.133.9 18.1%  
Current ratio x1.11.6 70.6%  
Inventory Days Days7436 205.2%  
Debtors Days Days41198 20.6%  
Net fixed assets Rs m1,0359,861 10.5%   
Share capital Rs m50341 14.7%   
"Free" reserves Rs m94212,331 7.6%   
Net worth Rs m1,71616,139 10.6%   
Long term debt Rs m04,706 0.0%   
Total assets Rs m4,15633,146 12.5%  
Interest coverage xNM1.6-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.10.6 183.5%   
Return on assets %-0.18.1 -1.5%  
Return on equity %-0.36.9 -4.3%  
Return on capital %012.3 0.0%  
Exports to sales %5.721.4 26.7%   
Imports to sales %6.515.2 42.4%   
Exports (fob) Rs m2704,402 6.1%   
Imports (cif) Rs m3063,136 9.8%   
Fx inflow Rs m3754,402 8.5%   
Fx outflow Rs m4703,184 14.8%   
Net fx Rs m-961,219 -7.8%   
CASH FLOW
From Operations Rs m-82,437 -0.3%  
From Investments Rs m-146-6,265 2.3%  
From Financial Activity Rs m8622,490 34.6%  
Net Cashflow Rs m709-1,337 -53.0%  

Share Holding

Indian Promoters % 0.0 82.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.3 7.0%  
FIIs % 15.7 5.5 285.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 7.5 121.3%  
Shareholders   12,856 10,665 120.5%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT LTD.  GSK PHARMA  PANACEA BIOTECH  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

World Stocks Mixed as Global Market Rally Loses Momentum(RoundUp)

Global financial markets ended the week on a mixed note. In the US, the Dow industrials ended the week down 0.4%, while the S&P 500 declined 0.1%.

Related Views on News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

More Views on News

Most Popular

The Real Brave-hearts are Those Who Still Have Deposits in IDBI Bank(Vivek Kaul's Diary)

Nov 6, 2017

It makes no sense to continue banking with this bank.

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Large cap funds are more liquid(The Honest Truth)

Nov 6, 2017

Is the dangerous illiquidity risk in small-cap and mid-cap funds common to large-cap funds too?

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 17, 2017 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS